

From: [Trials](#)
To: [Ferguson, Brian](#); [Trials](#)
Cc: [Holland, Elizabeth J.](#); [James, William G.](#); [Cipriano, Linnea P.](#); [Weinger, Joshua](#); [Desai, Anish](#); [Weisswasser, Elizabeth](#); [Pepe, Christopher](#); [Kennedy, Natalie](#); [Patel, Priyata](#); [Gesior, Andrew](#)
Subject: RE: IPR2020-01318: Regeneron v. Novartis; Motion to Terminate Proceedings
Date: Tuesday, November 24, 2020 9:11:35 AM

Counsel:

The panel has reviewed Petitioner's request to file a motion to terminate the proceedings in IPR2020-01318 pursuant to 37 C.F.R. §§ 42.5(a), 42.71(a). The panel authorizes the request without the need for a conference call. Petitioner is authorized to file an "Unopposed Motion to Dismiss the Petition and to Terminate the Proceeding" (37 C.F.R. § 42.72) by December 8, 2020. Petitioner must indicate in the motion whether it is unopposed and what impact, if any, the termination has on the remaining petition in IPR2020-01317.

Regards,

Andrew Kellogg,
Supervisory Paralegal
Patent Trial and Appeal Board
USPTO
andrew.kellogg@uspto.gov
(571)272-7822

From: Ferguson, Brian <brian.ferguson@weil.com>
Sent: Friday, November 20, 2020 3:52 PM
To: Trials <Trials@USPTO.GOV>
Cc: Holland, Elizabeth J. <EHolland@goodwinlaw.com>; James, William G. <WJames@goodwinlaw.com>; Cipriano, Linnea P <LCipriano@goodwinlaw.com>; Weinger, Joshua <JWeinger@goodwinlaw.com>; Desai, Anish <anish.desai@weil.com>; Weisswasser, Elizabeth <Elizabeth.Weisswasser@weil.com>; Pepe, Christopher <Christopher.Pepe@weil.com>; Kennedy, Natalie <Natalie.Kennedy@weil.com>; Patel, Priyata <Priyata.Patel@weil.com>; Gesior, Andrew <Andrew.Gesior@weil.com>
Subject: IPR2020-01318: Regeneron v. Novartis; Motion to Terminate Proceedings

IPR2020-01318
Patent 9,220,631 B2

Dear Trial Board:

We are counsel of record for Petitioner Regeneron Pharmaceuticals in the above-identified IPR. Petitioner requests permission to file a motion to terminate the proceedings in IPR2020-01318 pursuant to 37 C.F.R. §§ 42.5(a), 42.71(a). Because the Board has not yet determined whether to institute a trial, dismissal of the Petition and termination of the proceedings will preserve the resources of the Board and the parties, and will promote efficiency as contemplated by 37 C.F.R. § 42.1(b). Co-pending IPR2020-01317, directed to the same patent, will remain pending for the

Board's consideration.

We have conferred with counsel for Patent Owner, copied on this email, and Patent Owner does not oppose Petitioner's contemplated motion. If necessary, the parties are available for a call with the Board on the following dates and times:

Monday, November 23 after 2 pm Eastern

Tuesday, November 24 after 1 pm Eastern

Wednesday, November 25 before 11 am Eastern.

Respectfully submitted,

Brian Ferguson
Backup Counsel for Petitioner



Brian E. Ferguson
Co-Head, Patent Litigation Group

Weil, Gotshal & Manges LLP
2001 M Street NW, Suite 600
Washington, DC 20036
brian.ferguson@weil.com
+1 202 682 7516 Direct
+1 301 801 8870 iPhone

The information contained in this email message is intended only for use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by email, postmaster@weil.com, and destroy the original message. Thank you.